Table 3B.
The outcomes in lung cancer patients among the included studies.
| Study | Median OS times | p-value | Survival rates, mortality | p-value | Outcome in multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| NN patients | HN patients | NN patients | HN patients | HR | 95% CI | p-value | ||||
| Allan et al. (39) | 7 months | 7 months | 0.06 | NR | NR | - | NI | - | - | NS |
| Li et al. (40) | NR | NR | - | 79.6% SR at 25 months | 73.83% SR at 25 months | - | NR | - | - | - |
| Osterlind et al. (41) | 40 weeks | 34 weeks | - | NR | NR | - | I | - | - | <0.05 |
| Doshi et al. (42) | 16 months | 11 months | <0.05 | 61.31% SR at 10 months | 54.16% SR at 10 months | - | I | 2.07 | 1.11–3.84 | <0.05 |
| Johnson et al. (43) | NR | NR | - | NR | NR | - | NI | - | - | NS |
| Sagman et al. (44) | 45 weeks | 42 weeks | 0.006 | NR | NR | - | NI | - | - | NS |
| Jacot et al. (45) | 18.7 months | 4.1 months | <0.0001 | NR | NR | - | I | 1.99 | 1.04–3.77 | S |
| Hong et al. (46) | 11.7 months | 10 months | 0.039 | 59.48% SR at 10 months | 49.69% SR at 10 months | - | NI | - | - | NS |
| Maestu et al. (47) | NR | NR | - | NR | NR | - | NI | - | - | NS |
| Kawahara et al. (48) | 11.4 months | 9.1 months | 0.0072 | NR | NR | - | NI | - | - | NS |
| Cerny et al. (49) | NR | NR | - | 59.48% SR at 10 months | 34% SR at 10 months | - | I | - | - | 0.0009 |
| Ma et al. (50) | 14.1 months | 7.6 months | <0.001 | 81.31% SR at 10 months | 32.83% SR at 10 months | - | NR | - | - | - |
| Umemura et al. (51) | 10.6 months | 10 months | 0.6653 | 50% SR at 10 months | 51.77% SR at 10 months | NS | NI | - | - | NS |
| Jacot et al. (52) | 7.5 months | 3.85 months | 0.0141 | NR | NR | - | I | 2.99 | 1.17–7.62 | 0.022 |
| Rechnitzer et al. (53) | 6.7 months | 3 months | <0.001 | NR | NR | - | I | - | - | <0.001 |
| Bose et al. (54) | NR | NR | <0.03 | NR | NR | - | NR | - | - | - |
| Rinaldi et al. (55) | 15.3 months | 10.3 months | 0.003 | NR | NR | - | I | 1.29 | 1.03–1.54 | 0.047 |
| Chan et al. (56) | NR | NR | - | NR | NR | - | NR | - | - | - |
| Huang et al. (57) | 14.5 months | 11 months | 0.008 | NR | NR | - | I | 1.49 | 1.04–2.13 | 0.03 |
OS, overall survival; NN, normonatremic; HN, hyponatremic; NR, Not reported; S-significant; NS, not significant; I, Independent factor; NI, Not independent factor; HR, hazard ratio; RR, risk ratio; SR, Survival rate; CI, confidence interval.